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ABSTRACT
Alzheimer’s disease (AD) is the most common progressive form of brain neurodegeneration and the most
prevailing cause of dementia. Unfortunately, the aetiology of AD is not completely studied but different
factors are associated with the development of AD such as among others low level of acetylcholine, aggre-
gation of b-amyloid (Ab), hyperphosphorylated tau protein, oxidative stress, and inflammation. The study
encompass organic syntheses of 2,3-dihydro-1H-cyclopenta[b]quinoline with 5,6-dichloronicotinic acid and
suitable linkers derivatives as multifunctional agents for AD treatment. Afterwards self-induced amyloid
beta aggregation, inhibition studies of acetylcholinesterase and butyrylcholinesterase and molecular dock-
ing studies were performed. The results showed that 3b compound exhibited the best acetylcholinesterase
inhibitory activity, with IC50 value of 0.052mM which is lower compared to references. Besides, all synthes-
ised compounds showed good butyrylcholinesterase inhibitory activity with IC50 values from 0.071 to
0.797mM. Compound 3b exhibited strong Ab1–42 aggregation inhibitory effect with 25.7% at 5mM to
92.8% at 100mM as well as good anti-inflammatory effect. Thus, new compounds could create new per-
spectives for further development as a multi-target-directed agent for AD treatment.
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Introduction
Alzheimer’s disease is a neurodegenerative, progressive disorder
of central nervous system (CNS) that generally affects aged peo-
ple. It is the most common cause of dementia which makes up
70% of senile dementia1. Today there are 47 million people living
with dementia worldwide. By 2050 this number will have
increased above 135 million2. The incidents of dementia rise with
increasing age. Dementia affects 3.9 persons out of 1000 at the
age ranging from 60 to 643. Although the advanced age, the his-
tory of family with AD and heredity are the main risk factors.
Researchers have identified another factors leading to AD, i.e.
head injury, stroke, heart disease, hypertension, mutation of ApoE
(ApoE4), hypercholesterolemia, diabetes mellitus type 2, insulin
resistance, obesity, and smoking4,5. Clinically, AD is characterised
by progressive decline of memory, learning processes, language,
and personality changes which reduce the ability to basic activ-
ities of daily living. Histological and morphological brain changes
in patients with AD is manifested by b-amyloids extracellular
deposits, hyperphosphorylation tau protein and creation of
neurofibrillary tangles inside neurons, impairment of cholinergic
system, oxidative stress, and neuroinflammation including high
levels of cytokines and resistin6–8. Abnormalities occur in cortical
and subcortical grey matter especially in hippocampus,
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parahippocampal gyrus, thalamus, amygdala, entorhinal, and pos-
terior cingulate cortex. The recent studies have showed that lon-
gitudinal white matter and white matter connected with limbic
system networks are also impaired at patients with AD. In add-
ition, the degeneration of white matter is not related with the
degeneration of grey matter, and it occurs earlier. It creates the
chance to earlier diagnosis before the first symptoms appear9–11.
This structural and metabolic changes CNS are used to diagnose
the purposes of AD including PET, MRI, DTI, and FA12–14.
Supplementary diagnostic method tests intellectual function use-
ful to determine the degree of mental impairment. Pathogenesis
of AD is mighty intricate. Researches have suggested several
hypotheses explaining pathomechanism of evolution of AD. There
are: cholinergic hypothesis (cholinergic dysfunction), b-amyloid
cascade (amyloid hypothesis), tau hyperphosphorylation, low con-
centration of steroids hormone, oxidative stress, and inflammation
theory. Among them cholinergic hypothesis is well documented
and has been globally validated. Abnormalities in central cholin-
ergic neurotransmission are the most characteristic features con-
nected with AD. The pathology of decreasing concentration of
acetylcholine (ACh) in synaptic cleft is a low activity of choline
acetyltransferase (ChAT), a specific enzyme that synthesises ACh
from choline and acetate. The correlation between reduced activ-
ity of ChAT and severity of AD symptoms is scientifically proved.
Besides ChAT acetylcholinesterase (AChE) and butyrylcholinester-
ase (BuChE) influence on cholinergic balance, which are two
types of enzyme hydrolyse ACh. At healthy individuals, AChE has
a crucial role in the regulation of the level of ACh while BuChE is
less active. However, patients with AD who were observed with
significant increase of BuChE activity (nonspecific esterase) corre-
lated with decrease in AChE activity4,15,16. Food and Drug
Administration (FDA) initially approved four acetylcholinesterase
inhibitors acting on central cholinergic neurotransmission: tacrine,
donepezil, galantamine, and rivastigmine. The first acetylcholin-
esterase reversible inhibitor approved by FDA against AD was tac-
rine. The mechanism of action tacrine is complicated and
involves several pathways: cholinergic, gabaergic, glutaminergic,
and nitrinergic. Nonetheless, the therapy with tacrine offers some
benefits, serious side-effects including hepatotoxicity, gastrointes-
tinal toxicity hypotension force FDA to withdraw tacrine from the
market. Memantine was the last passed drug at anti-AD therapy
and the first targeting the N-methyl-D-aspartate (NMDA) receptors
and glutaminergic neurotransmission. Scientists proved that
excess glutamate at synapses is associated with cytotoxicity and
participates in pathological mechanism of AD. Currently,
approved drugs provide only partial symptomatic relief and mod-
erate as well as elevate daily living ability4,5,17. Complicated
pathogenesis of AD requires new approaches to the drugs and
therapy. The recent studies are focused to create the drug affect-
ing on several pathways at the same time including cholinergic,
glutaminergic, gabaergic, nitrinergic, and influence on b-amyloid
and tau protein. This multi-target directed ligands (MTDLs) gener-
ate a new possibility of the therapy of AD. The MTDLs strategy is
reflected by many new researches of tacrine derivatives. The pur-
pose of the research is to increase activity and selectivity of
derivatives, improve of pharmacokinetics, reduce side-effects of
tacrine, and target on another pathomechanism. According to
MTDLs theory, our researches are also focused on a development
of new tetrahydroacridine derivatives as potential drugs against
AD. From synthesised compounds containing multi-functional
ligands and tacrine moiety, the most interesting are cholinester-
ase inhibitors creating double binding with catalytic anionic site
(CAS), and peripheral anionic site (PAS) characterised also as
inhibitors of Ab4,8,15–23.
Materials and methods
Chemistry
All the chemical reagents used in the synthesis were obtained
from commercial sources. 1H spectra were recorded on a Brucker
Advance III 600MHz spectrometer using DMSO-d6 or methanol-d4
as solvents. The chemical shifts were reported in parts per million
(ppm), using tetramethylsilane (TMS) as an internal reference. High
resolution mass spectra (HRMS) analysis was performed with the
use of Agilent Accurate-Mass Q-TOF LC/MS G6520B system with
dual electrospray (DESI) source (Agilent Technologies, Santa Clara,
CA). The detector in the analysis was tuned in a positive mode
with the use of Agilent ESI-L tuning mix in high resolution mode
(4 GHz). The IR spectra were recorded in attenuated total reflect-
ance (ATR) mode (Thermo Scientific Nicolet 6700, Thermo Electron
Scientific Instruments Corporation, Madison, WI). Fourier transform
was infrared spectrometer with smart ITR diamond adapter
(Madison, WI). Conducted reactions were monitored by the thin
layer chromatography (TLC). Anhydrous Na2SO4 was used to dry-
ing organic solutions. Melting points were determined using an
Electrothermal apparatus with open capillaries and were uncor-
rected. The solvents were removed by rotary evaporation under
reduced pressure. Flash chromatography – purifying technique,
was performed using silica gel 60 (Merck). Intermediates 1a–1h
were prepared according to the previously literature method24.
General procedure for the synthesis of compounds 2a–2h
A mixture of the tetrahydrofuran (THF) (8ml), 2-chloro-4,6-dime-
thoxy-1,3,5-triazine (CDMT) (0.16–0.59 g, 0.91–3.36mM), 5,6-dichlor-
onicotinic acid (0.18–0.65 g, 0.9–3.4mM) and dropwise of
N-methylomorpholine (0.09–0.36 g, 0.91–3.36mM) were added.
The reaction was carried out about 2 h in the ice bath. Then
(0.22–1.00 g, 0.91–3.36mM) of proper diamine dissolved in THF
(3ml) was added to the mixture and the reaction has been con-
tinuing at room temperature for 24 h with stirring. Purification was
performed by flash chromatography to give compounds 2a–2h in
good yield. Physical and spectral data are listed below.
5,6-Dichloro-N-[2-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-ethyl]-nicotinamide (2a)
Yield: 85%; beige solid; mp 175–178 C; IR (KBr)  (cm1): 765.7;
1228.2; 1332.5; 1432.5; 1563.5; 2946.2; 3260.4; 1H NMR (600MHz,
CD3OD) d 8.70 (1H, s, Ar), 8.35 (1H, d, J¼ 8.4 Hz, Ar), 8.32 (1H, s,
Ar), 7.91 (1H, t, J¼ 8.1 Hz, Ar), 7.78 (1H, d, J¼ 8.4 Hz, Ar), 7.70 (1H,
t, J¼ 7.9 Hz, Ar), 4.13 (2H, t, J¼ 6.0 Hz, CH2), 3.81 (2H, t, J¼ 5.9 Hz,
CH2), 3.50–3.45 (2H, m, CH2), 3.25–3.19 (2H, m, CH2), 2.34 (2H, p,
J¼ 7.8 Hz, CH2) (protons of NH groups invisible); MS (ESI) m/z:
400.1, 217.0, 185.1; MS-HR (ESI) calcd for C20H18Cl2N4O: 400.08577,
found: 400.08768.
5,6-Dichloro-N-[3-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-propyl]-nicotinamide (2b)
Yield: 85%; beige solid; mp 131–133 C; IR (KBr)  (cm1): 754.5;
1243.1; 1332.1; 1421.9; 1562.7; 2945.8; 3218.5; 1H NMR (600MHz,
CD3OD) d 8.74 (1H, s, Ar), 8.39 (1H, d, J¼ 8.5 Hz, Ar) 8.34 (1H, s,
Ar), 7.89 (1H, t, J¼ 7.7 Hz, Ar), 7.76 (1H, d, J¼ 8.8 Hz, Ar), 7.67 (1H,
t, J¼ 7.8 Hz, Ar), 3.96 (2H, t, J¼ 6.7 Hz, CH2), 3.62 (2H, t, J¼ 6.6 Hz,
CH2), 3.43 (2H, t, J¼ 7.3 Hz, CH2), 3.25–3.19 (2H, m, CH2), 2.32 (2H,
p, J¼ 7.7 Hz, CH2), 2.10 (2H, p, J¼ 6.8 Hz, CH2) (protons of NH
groups invisible); MS (ESI) m/z: 414.1, 231.0, 185.1; MS-HR (ESI)
calcd for C21H20Cl2N4O: 414.10142, found: 414.10127.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 159
5,6-Dichloro-N-[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-butyl]-nicotinamide (2c)
Yield: 78%; beige solid; mp 117–118 C; IR (KBr)  (cm1): 758.1;
1227.8; 1363.6; 1417.8; 1556.1; 2938.9; 3258.9; 1H NMR (600MHz,
CD3OD) d 8.68 (1H, s, Ar), 8.32–8.27 (2H, m, Ar), 7.83 (1H, t,
J¼ 7.7 Hz, Ar), 7.73 (1H, d, J¼ 8.7 Hz, Ar), 7.61 (1H, t, J¼ 7.8 Hz, Ar),
3.87 (2H, t, J¼ 7.0 Hz, CH2), 3.48 (2H, t, J¼ 6.8 Hz, CH2), 3.43–3.37
(2H, m, CH2), 3.17 (2H, t, J¼ 7.9 Hz, CH2), 2.29 (2H, p, J¼ 7.8 Hz,
CH2), 1.89–1.78 (4H, m, CH2) (protons of NH groups invisible); MS
(ESI) m/z: 428.1, 239.2, 185.1; MS-HR (ESI) calcd for C22H22Cl2N4O:
428.11707, found: 428.11843.
5,6-Dichloro-N-[5-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-pentyl]-nicotinamide (2d)
Yield: 76%; beige solid; mp 80–83 C; IR (KBr)  (cm1): 752.4;
1250.7; 1365.8; 1411.2; 1538.2; 2931.3; 3259.2; 1H NMR (600MHz,
CD3OD) d 8.63 (1H, s, Ar), 8.28 (2H, d, J¼ 8.7 Hz, Ar) 8.24 (1H, s,
Ar), 7.83 (1H, t, J¼ 8.2 Hz, Ar), 7.71 (1H, d, J¼ 8.8 Hz, Ar), 7.60 (1H,
t, J¼ 8.4 Hz, Ar), 3.85 (2H, t, J¼ 7.1 Hz, CH2), 3.43 (4H, dt, J¼ 24.5,
7.1 Hz, CH2), 3.19 (2H, t, J¼ 7.9 Hz, CH2), 2.31 (2H, p, J¼ 7.8 Hz,
CH2), 1.85 (2H, p, J¼ 15.1, 7.4 Hz, CH2), 1.74 (2H, p, J¼ 7.0 Hz, CH2),
1.56 (2H, p, J¼ 7.7, 7.2 Hz, CH2) (protons of NH groups invisible);
MS (ESI) m/z: 442.1, 253.2, 185.1; MS-HR (ESI) calcd for
C23H24Cl2N4O: 442.13272, found: 442.13243.
5,6-Dichloro-N-[6-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-hexyl]-nicotinamide (2e)
Yield: 62%; beige solid; mp 83–84 C; IR (KBr)  (cm1): 753.3;
1229.6; 1361.9; 1411.1; 1539.7; 2932.2; 3234.4; 1H NMR (600MHz,
CD3OD) d 8.70 (1H, s, Ar), 8.33 (1H, s, Ar), 8.26 (1H, d, J¼ 8.2 Hz,
Ar), 7.79 (1H, t, J¼ 7.7 Hz, Ar), 7.74 (1H, d, J¼ 8.3 Hz, Ar), 7.57 (1H,
t, J¼ 7.7 Hz, Ar), 3.79 (2H, t, J¼ 7.2 Hz, CH2), 3.42 (2H, t, J¼ 7.1 Hz,
CH2), 3.37 (2H, t, J¼ 7.3 Hz, CH2), 3.14 (2H, t, J¼ 7.9 Hz, CH2), 2.27
(2H, p, J¼ 7.8 Hz, CH2), 1.79 (2H, p, J¼ 7.6, 7.2 Hz, CH2), 1.68 (2H, p,
J¼ 7.3 Hz, CH2), 1.57–1.46 (4H, m, CH2) (protons of NH groups
invisible); MS (ESI) m/z: 456.2, 267.2, 185.1; MS-HR (ESI) calcd for
C24H26Cl2N4O: 456.14837, found: 456.15006.
5,6-Dichloro-N-[7-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-heptyl]-nicotinamide (2f)
Yield: 64%; beige solid; mp 70–74 C; IR (KBr)  (cm1): 755.9;
1227.9; 1359.5; 1411.9; 1526.2; 2931.8; 3247.0; 1H NMR (600MHz,
CD3OD) d 8.71 (1H, s, Ar), 8.33 (1H, s, Ar), 8.24 (1H, d, J¼ 3.4 Hz,
Ar), 8.23 (1H, d, J¼ 3.4 Hz, Ar), 7.75 (1H, t, J¼ 8.6 Hz, Ar), 7.56 (1H,
t, J¼ 7.3 Hz, Ar), 3.80–3.74 (2H, m, CH2), 3.43–3.37 (4H, m, CH2),
3.13 (2H, t, J¼ 7.8 Hz, CH2), 2.30–2.21 (2H, m, CH2), 1.77 (2H, m,
CH2), 1.72–1.60 (2H, m, CH2), 1.56–1.45 (6H, m, CH2) (protons of
NH groups invisible); MS (ESI) m/z: 470.2, 281.2, 185.1; MS-HR (ESI)
calcd for C25H30Cl2N4O: 470.16402, found: 470.16412.
5,6-Dichloro-N-[8-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-octyl]-nicotinamide (2g)
Yield: 76%; beige solid; mp 74–75 C; IR (KBr)  (cm1): 755.2;
1227.7; 1357.9; 1411.8; 1518.8; 2929.3; 3242.1; 1H NMR (600MHz,
CD3OD) d 8.72 (1H, s, Ar), 8.35 (1H, s, Ar), 8.10 (1H, d, J¼ 8.7 Hz,
Ar), 7.75 (1H, d, J¼ 8.4 Hz, Ar), 7.61 (1H, t, J¼ 7.7 Hz, Ar), 7.42 (1H,
t, J¼ 7.7 Hz, Ar), 3.69–3.63 (2H, m, CH2), 3.40–3.35 (2H, m, CH2),
3.31–3.25 (2H, m, CH2), 3.02 (2H, t, J¼ 7.8 Hz, CH2), 2.18 (2H, p,
J¼ 7.6 Hz, CH2), 1.70 (2H, p, J¼ 7.4 Hz, CH2), 1.60–1.65 (2H, m,
CH2), 1.31–1.45 (8H, m Hz, CH2) (protons of NH groups invisible);
MS (ESI) m/z: 484.2, 295.2, 185.1; MS-HR (ESI) calcd for
C26H30Cl2N4O: 484.17967, found: 484.18029.
5,6-Dichloro-N-[9-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-nonyl]-nicotinamide (2h)
Yield: 68%; beige solid; mp 73–75 C; IR (KBr)  (cm1): 754.6;
1211.6; 1358.7; 1425.1; 1522.1; 2928.6; 3204.8; 1H NMR (600MHz,
CD3OD) d 8.72 (1H, s, Ar), 8.35 (1H, s, Ar), 8.19 (1H, d, J¼ 8.5 Hz,
Ar), 7.75 (1H, d, J¼ 8.3 Hz, Ar), 7.71 (1H, t, J¼ 7.5 Hz, Ar), 7.51 (1H,
t, J¼ 7.7 Hz, Ar), 3.72 (2H, t, J¼ 7.3 Hz, CH2), 3.38 (2H, t, J¼ 7.0 Hz,
CH2), 3.31–3.35 (2H, m, CH2), 3.09 (2H, t, J¼ 7.8 Hz, CH2), 2.19–2.25
(2H, m, CH2), 1.73 (2H, p, J¼ 7.2 Hz, CH2), 1.60–1,64 (2H, m, CH2),
1.42–1,50 (10H, m, CH2) (protons of NH groups invisible); MS (ESI)
m/z: 498.2, 309.2, 185.1; MS-HR (ESI) calcd for C27H32Cl2N4O:
498.19532, found: 498.19592.
General procedure for the synthesis of compounds 3a–3h
Compounds 2a (0.020 g, 0.050mM), 2b (0.020 g, 0.048mM), 2c
(0.020 g, 0.047mM), 2d (0.020 g, 0.045mM), 2e (0.020 g, 0.044mM),
2f (0.020 g, 0.043mM), 2g (0.020 g, 0.041mM), and 2h (0.020 g,
0.040mM), were dissolved in methanol (1ml). Then, 4ml of HCl/
ether was added to the mixture and the reaction was stirred for
10min. After 24 h, precipitates were formed, isolated by filtration
and dried. In this synthesis 3a–3h compounds were obtained.
Physical and spectral data are listed below.
5,6-Dichloro-N-[2-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-ethyl]-nicotinamide hydrochloride (3a)
Yield: 43%; brown solid; mp 180–182 C; IR (KBr)  (cm1): 759.1;
1228.3; 1371.2; 1414.7; 1544.5; 2931.1; 3219.5; 1H NMR (600MHz,
DMSO-d6) d 14.02 (1H, s, HCl), 9.19 (1H, t, J¼ 5.7 Hz, NH), 8.77 (1H,
s, Ar), 8.50 (1H, d, J¼ 8.5 Hz, Ar), 8.45 (1H, s, Ar), 7.88 (1H, d,
J¼ 7.9 Hz, Ar), 7.83 (1H, d, J¼ 7.6 Hz, Ar), 7.66 (1H, d, J¼ 8.3 Hz, Ar),
4.08 (1H, s, NH), 3.95 (2H, q, J¼ 6.4 Hz, CH2), 3.61 (2H, q, J¼ 6.2 Hz,
CH2), 3.31–3.36 (2H, m, CH2), 3.15 (2H, t, J¼ 7.9 Hz, CH2), 2.19 (2H,
p, J¼ 7.7 Hz, CH2) (protons of NH groups invisible); MS (ESI) m/z:
400.1, 217.0, 185.1; MS-HR (ESI) calcd for C20H19Cl3N4O: 400.08577,
found: 400.08590.
5,6-Dichloro-N-[3-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-propyl]-nicotinamide hydrochloride (3b)
Yield: 36%; beige solid; mp 206–207 C; IR (KBr)  (cm1): 754.4;
1226.5; 1358.5; 1420.7; 1540.1; 2944.9; 3217.5; 1H NMR (600MHz,
DMSO-d6) d 13.86 (1H, s, HCl), 8.96 (1H, t, J¼ 5.6 Hz, NH), 8.77 (1H,
s, Ar), 8.44–8.47 (2H, m, Ar), 7.87 (1H, t, J¼ 8.0 Hz, Ar), 7.78 (1H, d,
J¼ 8.3 Hz, Ar), 7.63 (1H, t, J¼ 7.7 Hz, Ar), 4.08 (1H, s, NH), 3.83 (2H,
q, J¼ 6.7 Hz, CH2), 3.44 (2H, q, J¼ 6.3 Hz, CH2), 3.26–3.35 (2H, m,
CH2), 3.14 (2H, t, J¼ 7.9 Hz, CH2), 2.15 (2H, p, J¼ 7.7 Hz, CH2), 1.98
(4H, p, J¼ 7.0 Hz, CH2) (protons of NH groups invisible); MS (ESI)
m/z: 414.1, 231.0, 185.1; MS-HR (ESI) calcd for C21H21Cl3N4O:
400.08577, found: 400.08590.
5,6-Dichloro-N-[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-butyl]-nicotinamide hydrochloride (3c)
Yield: 56%; beige solid; mp 139–141 C; IR (KBr)  (cm1): 754.7;
1227.3; 1362.3; 1415.1; 1538.2; 2937.4; 3234.7; 1H NMR (600MHz,
DMSO-d6) d 13.92 (1H, s, HCl), 8.85 (1H, t, J¼ 5.5 Hz, NH), 8.77
(1H, s, Ar), 8.48 (1H, d, J¼ 8.5 Hz, Ar), 8.46 (1H, s, Ar), 7.87
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(1H, t, J¼ 7.6 Hz, Ar), 7.80 (1H, d, J¼ 8.3 Hz, Ar), 7.64 (1H, t,
J¼ 7.7 Hz, Ar), 4.02 (1H, s, NH), 3.76 (2H, q, J¼ 6.7 Hz, CH2),
3.38–3.33 (4H, m, CH2), 3.14 (2H, t, J¼ 7.9 Hz, CH2), 2.16 (2H, p,
J¼ 7.7 Hz, CH2), 1.75 (2H, p, J¼ 6.8 Hz, CH2), 1.67 (2H, p,
J¼ 6.8 Hz, CH2) (protons of NH groups invisible); MS (ESI) m/z:
428.1, 239.2, 185.1; MS-HR (ESI) calcd for C22H23Cl3N4O:
428.11707, found: 428.11698.
5,6-Dichloro-N-[5-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-pentyl]-nicotinamide hydrochloride (3d)
Yield: 50%; brown solid; mp 120–122 C; IR (KBr)  (cm1): 756.7;
1225.6; 1354.4; 1420.4; 1563.6; 2936.1; 3218.6; 1H NMR (600MHz,
DMSO-d6) d 13.81 (1H, s, HCl), 8.73–8.76 (2H, m, Ar, NH), 8.44
(1H, d, J¼ 8.5 Hz, Ar), 8.41 (1H, s, Ar), 7.86 (1H, t, J¼ 7.6 Hz, Ar),
7.77 (1H, d, J¼ 8.1 Hz, Ar), 7.62 (1H, t, J¼ 8.0 Hz, Ar), 4.08 (1H, s,
NH), 3.73 (2H, q, J¼ 6.7 Hz, CH2), 3.29–3.33 (4H, m, CH2), 3.14 (2H,
t, J¼ 7.9 Hz, CH2), 2.18 (2H, p, J¼ 7.8 Hz, CH2), 1.72 (2H, p,
J¼ 7.6 Hz, CH2), 1.61 (2H, p, J¼ 6.9 Hz, CH2), 1.44 (2H, p, J¼ 8.4 Hz,
CH2) (protons of NH groups invisible); MS (ESI) m/z: 442.1, 253.2,
185.1; MS-HR (ESI) calcd for C23H25Cl3N4O: 442.13272, found:
442.13368.
5,6-Dichloro-N-[6-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-hexyl]-nicotinamide hydrochloride (3e)
Yield: 53%; beige solid; mp 97–99 C; IR (KBr)  (cm1): 755.6;
1229.4; 1359.5; 1426.1; 1584.6; 2936.2; 3234.9; 1H NMR (600MHz,
DMSO-d6) d 13.79 (1H, s, HCl), 8.79 – 8.73 (2H, m, Ar, NH),
8.48–8.43 (1H, m, Ar), 7.88 (1H, t, J¼ 7.8 Hz, Ar), 7.79 (1H, d,
J¼ 7.9 Hz, Ar), 7.65 (1H, t, J¼ 8.2 Hz, Ar), 4.07 (1H, s, NH), 3.72 (2H,
q, J¼ 7.0 Hz, CH2), 3.24–3.33 (4H, m, CH2), 3.14 (2H, t, J¼ 7.8 Hz,
CH2), 2.18 (2H, p, J¼ 7.8, 7.1 Hz, CH2), 1.69 (2H, p, J¼ 15.2, 7.4 Hz,
CH2), 1.56 (2H, p, J¼ 15.5, 7.5 Hz, CH2), 1.45–1.36 (2H, m, CH2) (pro-
tons of NH groups invisible); MS (ESI) m/z: 456.1, 267.2, 185.1; MS-
HR (ESI) calcd for C24H27Cl3N4O: 456.14837, found: 456.14885.
5,6-Dichloro-N-[7-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-heptyl]-nicotinamide hydrochloride (3f)
Yield: 57%; beige solid; mp 100–102 C; IR (KBr)  (cm1): 757.5;
1228.1; 1360.1; 1424.3; 1557.4; 2929.8; 3227.7; 1H NMR (600MHz,
DMSO-d6) d 13.82 (1H, s, HCl), 8.80–8.75 (2H, m, Ar, NH), 8.48–8.43
(1H, m, Ar), 7.88 (1H, t, J¼ 7.4 Hz, Ar), 7.80 (1H, d, J¼ 8.1 Hz, Ar),
7.65 (1H, t, J¼ 7.6 Hz, Ar), 5.33 (1H, s, NH), 3.72 (2H, q, J¼ 6.9 Hz,
CH2), 3.26–3.28 (4H, m, CH2), 3.15 (2H, t, J¼ 7.9 Hz, CH2), 2.18 (2H,
p, J¼ 7.7 Hz, CH2), 1.72–1.64 (2H, m, CH2), 1.52–1.56 (2H, p,
J¼ 13.5, 6.1 Hz, CH2), 1.34–1.41 (4H, m, CH2) (protons of NH groups
invisible); MS (ESI) m/z: 470.1, 281.1, 185.1; MS-HR (ESI) calcd for
C25H29Cl3N4O: 470.16402, found: 470.16425.
5,6-Dichloro-N-[8-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-octyl]-nicotinamide hydrochloride (3g)
Yield: 56%; beige solid; mp 97–98 C; IR (KBr)  (cm1): 761.9;
1227.8; 1358.7; 1422.6; 1557.7; 2926.3; 3220.6; 1H NMR (600MHz,
DMSO-d6) d 13.84 (1H, s, HCl), 8.80–8.74 (2H, m, Ar, NH), 8.49–8.44
(1H, m, Ar), 7.88 (1H, J¼ 7.7 Hz, Ar), 7.80 (1H, d, J¼ 7.9 Hz, Ar), 7.65
(1H, t, J¼ 7.7 Hz, Ar), 5.34 (1H, s, NH), 3.71 (2H, q, J¼ 6.7 Hz, CH2),
3.25–3.29 (4H, m, CH2), 3.15 (2H, t, J¼ 7.9 Hz, CH2), 2.18 (2H, p,
J¼ 7.7 Hz, CH2), 1.68 (2H, p, J¼ 8.1, 7.6 Hz, CH2), 1.53 (2H, p,
J¼ 6.9, 5.7 Hz, CH2), 1.36–1.41 (6H, m, CH2) (protons of NH groups
invisible); MS (ESI) m/z: 484.2, 295.2, 185.1; MS-HR (ESI) calcd for
C26H31Cl3N4O: 484.17967, found: 484.1805.
5,6-Dichloro-N-[9-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-
ylamino)-nonyl]-nicotinamide hydrochloride (3h)
Yield: 37%; beige solid; mp 88–89 C; IR (KBr)  (cm1): 757.9;
1227.9; 1359.7; 1424.3; 1557.9; 2925.6; 3223.4; 1H NMR (600MHz,
DMSO-d6) d 13.97 (1H, s, HCl), 8.78–8.81 (2H, m, Ar, NH), 8.51–8.46
(1H, m, Ar), 7.86–7.89 (1H, m, Ar), 7.83 (1H, d, J¼ 8.2 Hz, Ar), 7.65
(1H, t, J¼ 7.7 Hz, Ar), 3.92 (1H, s, NH), 3.71 (2H, q, J¼ 6.8 Hz, CH2),
3.25–3.29 (4H, m, CH2), 3.15 (2H, t, J¼ 7.9 Hz, CH2), 2.18 (2H, p,
J¼ 7.7 Hz, CH2), 1.67 (2H, p, J¼ 7.8 Hz, CH2), 1.52 (2H, p, J¼ 6.7 Hz,
CH2), 1.35–1.41 (8H, m, CH2) (protons of NH groups invisible); MS
(ESI) m/z: 498.2, 309.2, 185.1; MS-HR (ESI) calcd for C27H33Cl3N4O:
498.19532, found: 498.18591.
In vitro inhibition studies on AChE and BuChE
The inhibitory activities of the tested compounds towards AChE
and BuChE were performed using Ellman’s method25. All reagents
including AChE (EC 3.1.1.7, from Electrophorus electricus), BuChE
(EC 3.1.1.8, from equin serum), DTNB (Ellman’s reagent), and ace-
tylthiocholine iodide (ATC iodide) were purchased from Sigma
Aldrich (Steinheim, Germany). Analysis was executed in following
procedure: AChE and BuChE solution was made by dissolving
enzymes in phosphate buffer (pH 7.4) to obtain 2 and 4U/ml,
respectively. Stock solutions of the tested compounds were pre-
pared in phosphate buffer (pH 7.4) with nine concentrations in the
range of 0.009–2.3 mM. The study was performed in triplicate and
recorded in 96-well microplates, using multifunctional microplate
reader. The assay medium contained DTNB solution 0.4mg/ml
(76 ml), AChE (10 ml), various concentration of the examined com-
pounds (14 ml) and ATC iodine solution (40ml) at the concentration
of 1mM. For the reference value, 14 ml of the test compound solu-
tions were replaced by phosphate buffer (pH 7.4). Next micro-
plates were incubated at room temperature and the absorption
(412 nm) was measured after 10min for the plates with AChE and
after 8min for BuChE. Inhibition activity was expressed as a per-
centage of the activity of the tested compound relative to the ref-
erence control. The obtained IC50 values expressed 50% inhibition
activity against AChE or BuChE.
Kinetic characterisation of AChE inhibition
The kinetic characterisation was evaluated according to the
Ellman’s method4,25. Plots of 1/velocity versus reciprocal substrate
concentration were constructed at different final concentrations of
the ATC iodide in the range of 100–10 mM gradually decreased by
10 mM. The studies were performed using two final concentrations
of 3b inhibitor (1.0, 0.1 mM) and without this inhibitor. The tested
medium contained: DTNB solution (0.4mg/ml), AChE solution (2U/
ml), solution of the examined compound and different concentra-
tions of the substrate ACT iodide in a total volume of 140 mM.
Absorbance were detected at 412 nm at room temperature after
6min. Received date were calculated and presented on the
Lineweaver–Burk plot. Determinated the KM and Vmax values were
used to define the type of enzyme inhibition.
Kinetic characterisation of BuChE inhibition
Kinetic analysis was performed using Ellman’s test4,25. Plots of
reciprocal velocity versus reciprocal substrate concentration were
made at various final concentrations of the ATC iodide in the
range of 100–10 mM gradually decreased by 10 mM. The analysis
were prepared for three final concentrations of 3b inhibitor (1.11,
0.22, 0.56 mM) and without inhibitor. Total volume of tested
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medium (140 ml) comprised: DTNB solution (0.4mg/ml), BuChE
solution (4 U/ml), solution of the examined compound and differ-
ent concentrations of the substrate ATC iodide. Absorbance was
detected at 412 nm at room temperature after 8min. Results were
calculated and presented on the Lineweaver–Burk plot. Received
KM and Vmax values allowed to define the type of enzyme
inhibition.
Beta-amyloid assay
Recent finding about decline in AD suggest a relationship
between amyloid b peptide (Ab) accumulation and the neurode-
generative process. The Ab1–42 aggregation assay was established
using the Thioflavin T fluorescence method22,26,27. Experiment was
performed by incubating the peptides previously dissolved in
DMSO at room temperature for 24 h (final Ab1–42 concentration –
12.58lM) with or without the tested compounds at the different
concentrations (5, 10, 25, 50, and100 lM). After incubation all sam-
ples were diluted in PBS – phosphate buffer (pH 7.4) containing
Thioflavin T (5 lM). Subsequently, after 5min incubation with the
dye, fluorescence signal was measured (excitation wavelength
446 nm, emission wavelength 490 nm) on a monochromator based
multimode microplate reader (Synergy H1, Bio-Tek, Winooski, VT),
adapted for 96-well microtiter plates. Next the percent of inhib-
ition on aggregation was calculated by the following expression:
100 – (IFi/IFo 100). IFi and IFo were the fluorescence intensities
obtained for absorbance in the presence and absence of inhibi-
tors, respectively. The background values were deducted in the
calculations.
Cell culture and cytotoxicity assay
In the experiment, ATCC CCL-185 cell line was used (Epithelial cells
from human lungs, carcinoma). Cells were seeded on 96-wells
plate (F12 Thermo Fisher medium, Waltham MA) and incubated
for 24 h. Then the cells were treated with various concentrations
(0.22, 1.11, 2.22, 22.22, and 222.20 mM) of the tested compound
dissolved in methanol and incubated for 48 h. Final methanol con-
centration in each well was 1ml per 100 ml of medium. As a con-
trol, the same medium as for cells breeding was used with
addition of 1ml methanol and without studied compound. As a
positive control pure methanol was used. After the time of incuba-
tion, procedure was carried out according to Vybrant MTT Cell
Proliferation Assay Kit: cells were labelled with 10 ml of the 12mM
MTT stock solution, incubated at 37 C for 4 h, all medium but
25ml was removed from the wells, 50ml of DMSO was added, incu-
bated for 10min at 37 C and the absorbance at 540 nm was
measured28–30.
Assay was performed on human liver cells which were pur-
chased from the American Type Culture Collection (Rockville, MD).
The cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% foetal bovine serum, 50U/ml peni-
cillin, and 50lg/ml streptomycin at 37 C in a 5% CO2 incubator.
Cells were incubated for 24 h in DMEM with varying concentra-
tions of tacrine and 3b compound. Toxicity of tested substances
was determined by the method of Carmichael et al.31. Liver cells
were maintained as described above in 24-well plates. Cells were
incubated for 24 h with varying concentrations of tacrine and 3b
compound, after that medium was discarded, and the cells were
rinsed three times with phosphate-buffered saline (PBS). Then, the
cells were incubated for 30min in 1ml of PBS with 25ll of MTT
(5mg/ml). Medium was removed from the wells, and the cells
were lysed 1ml of DMSO with 20 ll of Sorensen’s buffer (0.1M
glycine with 0.1M NaCl, pH 10.5). The absorbance was measured
at the wavelength of 570 nm. Component-treated cells were calcu-
lated as a percent of each control cell lines.
Hyaluronidase inhibition test
The inhibition study of hyaluronidase was carried out by turbidi-
metric method adapted to the 96-well plates and described previ-
ously by Michel et al32,33. At the beginning, 20ml of the tested 3b
compound solution in monosodium phosphate buffer (pH 7.0)
with 40 ml of hyaluronidase solution (22.55 U/ml, hyaluronidase
from bovine testes Type I-S, Sigma Aldrich, Steinheim, Germany)
were added to the wells of 96-well microtiter plates. Mixture was
incubated in the dark at 37 C for 10min. Then, 40 ml of hyaluronic
acid solution (0.03%, Sigma Aldrich, Steinheim, Germany) in mono-
sodium phosphate buffer (pH 5.35) was added to the wells and
the plate was incubated in the dark at 37 C for 45min. At the
end, 300 ml of bovine serum albumin solution (0.1%, Serva) in
sodium acetate buffer (pH 3.75) was added to the wells and incu-
bated in the room temperature for 10min. The changes in turbid-
ity were measured at 600 nm by a microplate reader (BioTek,
Winooski, VT). The assay was run out in three experiments in tripli-
cate to calculate IC50 values. Heparin (WZF, Polfa) was used as a
positive control34.
The inhibition of hyaluronidase by the tested compound was
calculated following the equation:
% inhibition ¼ 100x 1 AHA  AAN
AHA  AHYAL
  
where AHA absorbance of solution without the enzyme (positive
control),
AHYAL absorbance of solution without the tested compound
(negative control), AAN  absorbance of solution with the tested
compound.
Molecular modelling
Acetyl- and butyrylcholinesterase structures were retrieved from
Protein Data Bank (PDB codes: 2CKM and 1P0I, respectively).
Before docking each protein was prepared in the following way:
protonation of all histidine residues were set to Ne, all hydrogen
atoms were added, ligand and water molecules were removed,
and all amino acid residues within radius of 10 Å from bis-(7)-
tacrine for AChE and 20Å from the glycerol molecule present in
the active centre of BChE were defined as the binding site. Docking
was performed with GoldSuite 5.1 (CCDC)35 using standard settings
of the genetic algorithm with population size 100, 5 islands, and
100,000 operations4,36. Three-dimensional structures of all ligands
were created with Corina on-line (Molecular Networks GmbH,
N€urnberg, Germany)37 was used to check atom types and assign
Gasteiger–Marsili charges38. Ten poses for each ligand were col-
lected and sorted by GoldScore (for AChE) and ChemScore (for
BChE) function value. PyMOL 0.99rc6 (DeLano Scientific LLC,
Philadelphia, PA)39 was used to visualise the results of docking.
ADMET analysis
The drug discovery is a time consuming and complex process
requiring multi-disciplinary approaches to develop riskless and
effective medicines. ADMET (Absorption, Distribution, Metabolism,
Excretion, and Toxicity) predictions are important initial steps
towards the development of novel pharmaceuticals in the fight
against Alzheimer’s disease. However, it has been reported that
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95% of drug candidate molecules fail in the development stages,
and 50% of such failures are caused by unsatisfactory ADMET
properties. To avoid this failure, we calculated among others for
all the compounds, as well as tacrine, the parameters that define
the “Rule of Five” which the drugs in general follow: molecular
weight lower than 500, number of hydrogen bond donors lower
or equal 5, number of hydrogen bond acceptors lower or equal
than 10 and log p lower than 5. It is necessary to develop in silico
methods that are faster, simpler and more cost-effective for evalu-
ating the ADMET properties of a molecule in advance. The ADMET
filtering was done with the help of ACD/Percepta version 14.0.0
(Advanced Chemistry Development, Inc., Metropolitan Toronto,
Canada)40–42.
Results and discussion
Chemistry
The synthesis of the final compounds was accomplished as illus-
trated in Scheme 1. Novel, multifunctional derivatives consists of
2,3-dihydro-1H-cyclopenta[b]quinoline with 5,6-dichloronicotinic
acid moiety using diamine linker have been carried out in two
steps. In order to obtain end products we have used intermediates
1a–1h based on reactions developed and published earlier16. New
compounds were obtained via the synthesis between 5,6-dichloro-
nicotinic acid, previously activated by 2-chloro-4,6-dimethoxy-
1,3,5-triazine (CDMT), dropwise addition of N-methylmorpholine
and reacted with compounds 1a–1h dissolved in tetrahydrofuran
at 5 C. Monitoring the reactions using TLC showed the reactions
were completed after 2h. Compounds 2a–2h were obtained with
satisfactory yield (62–85%, mean 74%) and purified by flash chro-
matography. The last step of the synthesis involved conversion of
the obtained compounds 2a–2h into hydrochlorides 3a–3h.
Compounds 2a–2h were dissolved in a small volume of methanol
and next HCl in ether was added.
Biological activity
To estimate the inhibitory activity towards AChE (from electric
eel) and BuChE (from equine serum) of new derivatives 3a–3h,
Ellman’s test was performed. As a reference compounds were
used tacrine and donepezil. The IC50 values of EeAChe and
EqBuChE inhibition is collected in Table 1. All synthesised com-
pounds are active AChE inhibitors with IC50 values in the range
of 0.052–0.744 mM. In comparison with tacrine only two com-
pounds (3c, 3d) were less active. Taking donepezil (0.103mM)
into consideration, 3a compound (0.065 mM), 3b (0.052 mM), and
3e (0.053 mM) showed higher potency. Analysis showed no sig-
nificant relationship between structure and the obtained IC50 val-
ues. Among the described compounds, 3b (0.052mM) revealed
the highest inhibitory potency against AChE, which in compari-
son to tacrine and donepezil, was about 3-times and 2-times
higher, respectively. Consequently, compound 3b was chosen for
the kinetic analysis of the AChE and BuChE inhibition.
All derivatives were also very active BuChE inhibitors and their
IC50 values ranged from 0.071 to 1.863 mM. The whole series
revealed significant higher activity than donepezil (11.826 mM),
although comparing with tacrine none of them showed higher
activity. The most active compound (3f) towards BuChE with
IC50¼ 0.071 mM presented 167-fold higher than donepezil.
The mechanism of EeAChE inhibition was investigated for
inhibitor 3b as the most valuable compound (IC50¼ 0.052 mM)
(Table 1). Lineweaver–Burk plot (Figure 1) presents 1/velocity ver-
sus 1/substrate concentrations in the range of 100–10mM grad-
ually decreased by 10 mM for different inhibitor 3b concentrations
(1.11, 0.11mM) and without inhibitor. Based on Lineweaver–Burk
plot’s analysis the mixed type of inhibition was elucidated. Lines
crossing in the same point of coordinate system. At increasing
inhibitor concentration KM values (110.18, 293.78, and 2185.33 mM)
and Vmax values (166.67, 312.50, and 1666.67 A/min) also increased
(Table 2).
The mechanism of EqBuChE inhibition for inhibitor 3b as the
most potent compound was revealed from Lineweaver–Burk plot
analysis (Figure 2). The reciprocal velocity was constructed as a
function of reciprocal substrate concentration in the range
Table 1. The activity of novel compounds 3a–3h against acetylcholinesterase
from electric eel and equine butyrylcholinesterase.
Compound
AChE
IC50 ± SEM (mM)
a
BuChE
IC50 ± SEM (mM)
b
Selectivity
for AChEc
Selectivity
for BuChEd
3a 0.065 ± 0.007 1.863 ± 0.083 28.593 0.035
3b 0.052 ± 0.002 0.158 ± 0.029 3.030 0.330
3c 0.744 ± 0.046 0.797 ± 0.086 1.071 0.934
3d 0.285 ± 0.038 0.460 ± 0.038 1.615 0.619
3e 0.053 ± 0.005 0.127 ± 0.014 2.380 0.420
3f 0.125 ± 0.021 0.071 ± 0.012 0.569 1.756
3g 0.152 ± 0.045 0.108 ± 0.006 0.711 1.407
3h 0.155 ± 0.045 0.082 ± 0.030 0.529 1.889
Donepezil 0.103 ± 0.016 11.826 ± 2.060 114.971 0.009
Tacrine 0.163 ± 0.041 0.020 ± 0.003 0.122 8.187
aIC50: 50% inhibitory concentration (means ± SEM of three independent experi-
ments) of AChE.
bIC50: 50% inhibitory concentration (means ± SEM of three independent experi-
ments) of BuChE.
cSelectivity for AChE: IC50(BuChE)/IC50(AChE).
dSelectivity for BuChE: IC50(AChE)/IC50(BuChE).
1a, 2a, 3a n=2
1b, 2b, 3b n=3
1c, 2c, 3c n=4
1d, 2d, 3d n=5
N
HN
(CH2)n
N HCl
ba
1e, 2e, 3e n=6
1f, 2f, 3f n=7
1g, 2g, 3g n=8
1h, 2h, 3h n=9
1a-h 2a-h 3a-h
NH2
HN
(CH2)n
HN
O
N
Cl
Cl
N
HN
(CH2)n
HN
O
N
Cl
Cl
Scheme 1. Synthesis of compounds 2a–2h and 3a–3h. Reagents: (a) 5,6-dichloronicotynic acid, CDMT, N-methylmorpholine, THF; (b) HCl/ether.
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10–100 mM gradually decreased by 10mM for different inhibitor 3b
concentrations (0.22, 0.56 mM) and without inhibitor. The analysis
showed increased KM values (10371.5, 3223.0, 1453.0, 536.5mM)
and increased Vmax values (3333.3, 1666.7, 769.2 A/min) with
higher inhibitor concentrations (Table 3). Lines crossing in the
same point in the Lineweaver–Burk plot revealed the mixed type
of inhibition.
The results (summarised in Table 4) (Figure 3) show that the
tested compound (3b) induced a decrease of the ThT fluorescence
associated with the Ab fibril binding. In all of presented concentra-
tions 3b compound presented aggregation inhibition values above
25%, whereas using 100mM of inhibitor concentration presented
the best activity (92.78%). At a concentration of 5mM and 10 mM
the tested compound showed the inhibition rate 25.67 and
25.76%, respectively. It means there is no significant difference;
however, the effect is important. As the concentration increased,
the inhibition rate also enhanced. At a concentration of 25 and
50mM the inhibition rate reached the values of 48.18 and 54.30%,
respectively. This relationship indicates dosage-dependent manner
of the inhibition.
Compound 3b which showed the highest inhibitory activity
towards AChE was further tested for the potential cytotoxic effect
using ATCC CCL-185 cell line (Epithelial cells from human lungs,
carcinoma). The cells are treated with novel compound at different
concentration ranging from 0.22 to 222.20 mM and showed in
Figure 4. The results were expressed as a percentage of cell
viability, assuming control as 100%. The results revealed no signifi-
cant different of cell viability (about 70%) in concentrations from
0.22 to 2.22mM. Using 22.22mM concentration of 3b compound
the cell viability suddenly decreased and in 222.20mM concentra-
tion it reached only about 7%. To sum up, the concentration of
3b derivative for 50% inactivation of AChE (0.052 mM) and BuChE
(0.158 mM) is lower than cytotoxicity effect for this compound.
Moreover, cytotoxicity assay performed on human liver cells
showed no toxic effect of tested compounds.
Inflammation is a complex biological response to aggressive
agents (pathogens, injury), involving local vascular system and
immune system. The inflammation is regulated by anti-inflamma-
tory mediators, including cytokines, chemokines, and by several
cellular enzymes, such as hyaluronidase. Hyaluronidase is an
enzyme responsible for hyaluronan depolymerisation and by this
process; it weakens the integrity of tissues during the inflamma-
tion. The prolonged inflammatory process is commonly associ-
ated with the development of some chronic disease, such as AD
or cancers. Mostly for the treatment of inflammatory diseases,
the non-steroidal anti-inflammatory (NSAIDs) are in common use.
Due to the many side effects, such as gastrointestinal, renal, and
cardiovascular toxicity, their use should be limited43. Therefore,
novel drugs with anti-inflammatory properties are being
investigated.
The spectrophotometric assay was performed in order to
determine the inhibitory effect of novel compound towards
hyaluronidase34. The inhibitory effect was tested in vitro as a dose-
dependent response. Table 5 presents IC50 values of novel
compound and reference drug (hyaluronidase inhibitor) – heparin.
3b compound presented high inhibitory activity towards hyaluro-
nidase (IC50 579.77 ± 16.28mM), although heparin was stronger
inhibitor (IC50 56.41 ± 0.78mM) (Figure 5). It can be conclude that
3b compound has good anti-hyaluronidase activity and may
decrease the risk of development of chronic disease.
Figure 1. Lineweaver–Burk reciprocal plots illustrating mixed-type of EeAChE inhibition by 3b compound. ATCh: acetylthiocholine; V: initial velocity rate.
Table 2. The Vmax and KM values at different 3b inhibitor concentrations for
AChE.
Concentration of inhibitor 3b (mM) KM (mM) Vmax (A/min)
1.11 2185.33 1666.67
0.11 293.78 312.50
0 110.18 166.67
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Molecular modelling
Molecular modelling studies were performed in order to analyse
the binding mode of the obtained compounds. In case of AChE
tested ligands presented two conformations which were depend-
ent on the length of the linker. Extended conformation was similar
to the conformation of bis-(7)-tacrine bound to the enzyme while
bent conformation corresponded to the conformation in which
the phenyl ring was located near the wall of the entrance to the
enzyme gorge. Ligands with short linkers occurred mostly in
the bent arrangements. On the other hand longer linkers led to
the extended orientation of the compounds. The most active
derivative 3b (Figure 6) is an example of the ligand with bent con-
formation. The cyclopentaquinoline moiety created a characteristic
p–p stacking and cation-p interactions with Trp84 and Phe330.
Tricyclic fragment was additionally stabilised by a hydrogen bond
between the protonated nitrogen atom and oxygen atom from
carbonyl group of His440 main chain. The linker was directed
towards the gorge wall near the entrance where the hydroxyl
group of Tyr121 participated in hydrogen bonding with ligand car-
bonyl oxygen. Chlorine-substituted pyridine ring was involved in
p–p stacking interactions with Phe288. Docking studies confirmed
that cyclopentaquinoline moiety mimicked the arrangement of for-
mer drug, tacrine in the active site. Tacrine received GoldScore
value equal to 58.44. The most active compound 3b, in the
described conformation, was assessed by the same scoring func-
tion at level of 81.28 which stayed in accordance with results of
biological studies. In the active site of BuChE similar conformations
of ligands were observed. Compounds with shorter linker pre-
sented bent conformation located deep inside active site of
enzyme. Molecules with longer linkers (6 and more carbon atoms)
appeared in extended conformation providing contact with a per-
ipheral anionic site. The binding mode of the most potent BuChE
inhibitor 3f is shown in Figure 7. Cyclopentaquinoline moiety par-
ticipated in p–p stacking and cation-p interactions with Trp82.
Long, aliphatic linker created hydrophobic interactions with
Tyr332. Chlorine-substituted nicotinamide was located at the
entrance to the binding site of the enzyme. That conformation
was preferable for the most active BuChE inhibitors among the
tested compounds. Comparing the most active inhibitor 3f and
tacrine, both cyclopentaquinoline and tetrahydroacridine moieties
occupied the same area within the active site of BuChE and inter-
acted in a similar way. The ChemScore value was equal to 106.78
for tacrine and 94.28 for compound 3f, respectively, and corre-
sponded to results of Ellman’s assay (see Table 1).
ADMET analysis
Various pharmacokinetic and pharmacodynamics properties of
compounds (absorption, distribution, metabolism, excretion, and
Figure 2. Lineweaver–Burk reciprocal plots illustrating mixed-type of EqBuChE inhibition by 3b compound. ATCh: acetylthiocholine; V: initial velocity rate.
Table 3. The Vmax and KM values at different 3b inhibitor concentrations for
BuChE.
Concentration of inhibitor 3b (mM) KM (mM) Vmax (A/min)
0.22 3223.0 3333.3
0.56 1453.0 1666.7
0 536.5 769.2
Table 4. Inhibition of Ab aggregation at different concentrations of com-
pound 3b.
3b compound
concentration (mM) Ab aggregation (%)
Inhibition of
Ab aggregation (%)
Control sample 100.00 0.00
5 74.31 25.69
10 74.23 25.77
25 51.82 48.18
50 45.70 54.30
100 7.22 92.78
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toxicity) were studied using in silico ADMET profiling (Table 6).
Physico-chemical indicators are increasingly used during the
early stages of drug discovery to provide a comprehensive under-
standing of the key properties that affect biological functions
(ADMET). Screening on the basis of blood brain barrier property is
important for any lead molecule to act as potent inhibitor against
Alzheimer’s disease. In particular, the new molecules should pre-
sent a good CNS penetration profile and low toxic effects. The
probability of positive Ames test for all new derivatives is much
lower in comparison to the reference (tacrine) which means lower
genotoxicity effect. Some of our compounds violated the “rule of
five”, for 3e, 3f, 3g, and 3h compounds log p is higher than 5. In
our study, all the tested compounds present good value of TPSA
(90) so it is predicted to penetrate CNS. Furthermore, com-
pounds presents sufficient brain penetration profile, log BB is not
lower than 1. The results for our compounds are estimated at
0.12–0.55 which confirms previous results. . All the structures
reported herein show suitable values (MW <460). To sum up, des-
pite that compounds show good brain penetration profiles, it can
Figure 3. Inhibition of Ab aggregation by compound 3b at different concentrations. Thioflavin T assay (kexc¼ 446nm; kem ¼ 490nm).
Figure 4. Effect of compound 3b on the viability of cells.
Table 5. All values are presented as the means ± standard devi-
ation (SD); IC50, 50% inhibition of enzyme activity.
Compound HYAL IC50 ± SD (mM)
3b 579.77 ± 16.28
Heparin 56.41 ± 0.78
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be concluded that structure 3b presents the best drug-like charac-
teristics and ADMET properties of the series44–46.
Conclusion
In conclusion, a series of cyclopentaquinoline hybrids were
designed and synthesised as multifunctional ChEIs. The biological
evaluation showed that all of the novel compounds were good
AChE/BuChE inhibitors in the micromolar range. Especially, 3b
derivative showed the highest potent ChEs inhibitory activities
which were 0.052 mM for AChE (3-times and 2-times more active
than tacrine and donepezil, respectively) and 0.158mM for BuChE
(75-times more active than donepezil). Some compounds were
highly selective for AChE (i.e. 3a, 3b, and 3e derivatives) and for
BuChE (i.e. 3f, 3g, and 3h derivatives). Kinetic assays and molecu-
lar modelling studies proved mixed-type of inhibition for 3b com-
pound for AChE and BuChE. In addition, the most active inhibitor
towards AChE exhibited significant inhibition of Ab (1–42) aggre-
gation (ranging from 25.69% at the concentration of 5mM to
92.78% at 100 mM). Additionally, examined 3b compound showed
Figure 5. 50% inhibition of hyaluronidase activity by 3b compound and heparin.
Figure 6. Binding mode of compound 3b within the active site of AChE.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 167
non cytotoxic properties (compared to the concentration of IC50)
and good anti-hyaluronidase activity (anti-inflammatory effect).
ADMET profiling of the compounds were done to obtain mole-
cules with important pharmacokinetic and pharmacodynamics
properties. 3b compound which was selected for further research
showed significant drug-like characteristics according to the
Lipinski’s rule of five. All the presented studies promote 3b com-
pound as a novel multifunctional agent for the treatment of AD,
as well as presented derivative might be considered for further
research as a promising target.
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